『The Peter Attia Drive』のカバーアート

The Peter Attia Drive

The Peter Attia Drive

著者： Peter Attia MD
無料で聴く

The Peter Attia Drive will feature guests and experts that will offer advice and insight to help you optimize performance, health, longevity, critical thinking, and life. It's hosted by Stanford M.D., TED speaker, and longevity expert Dr. Peter Attia, founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City.Copyright © Peter Attia, MD エクササイズ・フィットネス フィットネス・食生活・栄養 衛生・健康的な生活 身体的病い・疾患
エピソード
  • #399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

    #399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.
    2026/07/13

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter's Weekly Newsletter

    Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care.

    We discuss:

    • Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45];
    • How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15];
    • The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30];
    • Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45];
    • Why forgetting names is usually normal and when word-finding problems become concerning [29:00];
    • Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45];
    • The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15];
    • When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00];
    • Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15];
    • Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45];
    • The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00];
    • How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30];
    • Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30];
    • A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00];
    • Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00];
    • Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45];
    • Risk factors for Lewy body dementia and what remains unknown [1:36:15];
    • Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45];
    • How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15];
    • The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and
    • More.

    Connect With Peter on Twitter, Instagram, Facebook and YouTube
    続きを読む 一部表示
    1 時間 57 分
  • Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

    Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)
    2026/07/06
    View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably. We discuss: Peter's humorous experience talking nutrition with a second grader [3:00];Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30];Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45];The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00];Grip strength as a simple yet powerful predictor of all-cause mortality [17:15];Is muscle strength causal or just a marker of health? [20:30];Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00];How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15];How muscle mass and strength decline with age, and why it's essential to act early to slow decline and preserve function later in life [31:00];The foundational principles of building muscle strength and size through resistance training [36:00];How to apply "progressive overload" for long-term strength and muscle gains [40:00];The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [45:15];The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:45];How to effectively train for power [52:30];Training intensity: the benefits and safety of using the "reps in reserve" method [53:30];How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [56:15];Can bodyweight exercises build muscle as effectively as weight training? [58:15];How women can effectively build strength and muscle: key considerations [59:45];Effective methods for tracking progress in strength [1:01:45];Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:05:00];How to balance workout frequency with recovery for optimal results [1:07:15];How to recognize signs of overtraining and when to consider taking rest days [1:10:45];Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:45];Protein: recommended intake, quality sources, timing of consumption, and more [1:18:00];How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:45];Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:28:15];The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:29:15];How to structure an effective workout routine for a younger person who is new to resistance training [1:32:00];How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:36:00];Should beginners start with machines or free weights when resistance training? [1:37:00];How experienced lifters should modify their training to support healthspan and performance in later life [1:38:30]; andMore. Connect With Peter on Twitter, Instagram, Facebook and YouTube
    続きを読む 一部表示
    1 時間 44 分
  • #398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

    #398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss
    2026/06/29
    View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45];Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45];How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15];Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30];Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15];The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00];Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45];Why lean mass measurements are an imperfect proxy for muscle health and function [21:45];The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00];Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00];Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00];Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45];Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00];Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00];Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45];Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15];Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00];The risks of using gray-market retatrutide before FDA approval [52:15];Key takeaways [54:30]; andMore. Connect With Peter on Twitter, Instagram, Facebook and YouTube
    続きを読む 一部表示
    10 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません